Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer's disease and three causality networks: The GR@ACE project.
|
31473137 |
2019 |
Alzheimer's Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our main findings were i) we were able to build generalizable models with clinically relevant accuracy (~93%) for identifying MCI individuals who progress to AD within 3 years; ii) markers of AD pathophysiology (amyloid, tau, neuronal injury) accounted for large shares of the variance in predicting progression; iii) our methodology allowed us to discover that expression of CR1 (complement receptor 1), an AD susceptibility gene involved in immune pathways, uniquely added independent predictive value.
|
30783207 |
2019 |
Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
GWASCAT |
Shared genetic architecture between metabolic traits and Alzheimer's disease: a large-scale genome-wide cross-trait analysis.
|
30805717 |
2019 |
Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk.
|
30617256 |
2019 |
Alzheimer's Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
The involvement of CR1 in the pathogenesis of AD might be linked to insufficient clearance of amyloid deposits.
|
30044434 |
2018 |
Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
GWASCAT |
GWAS on family history of Alzheimer's disease.
|
29777097 |
2018 |
Alzheimer's Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Genetic polymorphisms in several genes, including APOE (Apolipoprotein E), PSEN1 (Presenilin 1), CR1 (Complement receptor 1), and PICALM (Phosphatidylinositol binding clathrin assembly protein), have been associated to an increased AD risk.
|
30040717 |
2018 |
Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
SNP effects on erythrocyte CR1 likely underlie the association of CR1 polymorphisms with AD risk.
|
29792870 |
2018 |
Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
The AD susceptibility genes apolipoprotein E (<i>APOE</i>), phosphatidylinositol binding clathrin assembly protein (<i>PICALM</i>), complement receptor 1 (<i>CR1</i>) and clusterin (<i>CLU</i>) are involved in the HSV lifecycle.
|
29559905 |
2018 |
Alzheimer's Disease
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
ADE levels of complement regulatory proteins CD59, CD46, decay-accelerating factor (DAF), and complement receptor type 1, but not factor I, were significantly lower for AD patients than controls (p < 0.0001 for CD59 and DAF), were diminished by the AD1 stage, and were further decreased at the AD2 stage.
|
29406582 |
2018 |
Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Complement receptor 1 gene (CR1) intragenic duplication and risk of Alzheimer's disease.
|
29675612 |
2018 |
Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
These data indicate that genetic variation within the CR1 gene is associated not only with Alzheimer's disease, but also with general cognitive function during late life.
|
29212848 |
2018 |
Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
However, to date, few studies were performed to discover the possible effect of CR1 genetic variants on AD pathology in the brain.
|
26742530 |
2017 |
Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
CR1 polymorphisms elevate AD risk, and >80% of human CR1 is vested in erythrocytes to subserve immune adherence.
|
28475854 |
2017 |
Alzheimer's Disease
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
As a receptor for the complement components C3b and C4b, CR1 regulates the activation of the complement cascade and promotes the phagocytosis of immune complexes and cellular debris, as well as the amyloid-beta (Aβ) peptide in Alzheimer's disease (AD).
|
28745649 |
2017 |
Alzheimer's Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
Single nucleotide polymorphisms (SNPs) in and near ABCA7, BIN1, CASS4, CD2AP, CD33, CELF1, CLU, complement receptor 1 (CR1), EPHA1, EXOC3L2, FERMT2, HLA cluster (DRB5-DQA), INPP5D, MEF2C, MS4A cluster (MS4A3-MS4A6E), NME8, PICALM, PTK2B, SLC24A4, SORL1, and ZCWPW1 have been associated with Alzheimer's disease (AD) in large meta-analyses.
|
27005436 |
2016 |
Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
GWASCAT |
A novel Alzheimer disease locus located near the gene encoding tau protein.
|
25778476 |
2016 |
Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Recent large genome wide association studies (GWAS) have identified single nucleotide polymorphisms (SNPs) in the C3b/C4b receptor (CR1 or CD35) that are associated with late onset AD.
|
26914463 |
2016 |
Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Our analysis further supports previous findings that the CR1 rs6656401 polymorphism contributes to AD susceptibility.
|
24878768 |
2015 |
Alzheimer's Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
These observations indicate that AD susceptibility is associated with the long CR1 isoform (CR1*2), albeit at a lower density, suggesting that AD results from insufficient clearance of plaque deposits rather than increased inflammation.
|
25666996 |
2015 |
Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
GWASCAT |
Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease.
|
24162737 |
2013 |
Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
GWASDB |
Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease.
|
24162737 |
2013 |
Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We investigated the influence of the rs6656401 single nucleotide polymorphisms (SNP) of the CR1 gene, the rs3851179 SNP of the PICALM gene, and the rs11136000 SNP of the CLU gene on risk of AD in a Polish population.
|
23650005 |
2013 |
Alzheimer's Disease
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
These findings question a role for the Ser1610Thr variant in AD risk and related endophenotypes, and reaffirm our previous observation that the CR1 CNV could be the true functional risk factor explaining the association between CR1 and AD.
|
23582656 |
2013 |
Alzheimer's Disease
|
0.500 |
Biomarker
|
disease |
BEFREE |
How precisely the different functional role of CR1-S in the immune complement cascade contributes to AD pathogenesis will need additional functional studies.
|
21403675 |
2012 |